



SomnoMed introduces new Medical Product

Novel diagnostic appliance enables sleep physicians to identify candidacy for oral appliances without disturbing the patient.

29th June 2010, Sydney: SomnoMed Limited (ASX:SOM)

At SLEEP 2010 held in San Antonio, Texas in June 2010, SomnoMed introduced the new SomnoMed RCMP pre-production product, which is to be released in 2011, subject to FDA approval. The RCMP is a diagnostic tool designed to be used by Sleep Physicians to measure and control protrusion of the mandible during a polysomnographic study (PSG). It is anticipated the results of a study using the RCMP will help Sleep Physicians identify suitable patients for the SomnoMed MAS oral appliance therapy.

Invented by Professor and Sleep Physician, Dr. John Remmers, the RCMP is the result of the collaboration between SomnoMed Limited, Zephyr Sleep Technologies Inc. and the University of Calgary. Based on two published studies using pre-cursor technologies, it is predicted that the RCMP will enable improved patient care through selection and titration of patients suitable for an oral device. In addition it is anticipated to forge links and develop critical relationships between the Sleep Physician and Dentists.

“The RCMP will answer the question of a predictable outcome for SomnoDent® patients and it confirms our leading role as an innovator in Dental Sleep Medicine worldwide,” states Ralf Barschow, CEO of SomnoMed. “Sleep Technicians and Sleep Physicians will soon be able to control and measure the impact of an oral appliance in a clinical environment, which will allow professionals to predict the effectiveness of MAS treatment. The RCMP addresses a key strategic objective in providing further support for the acceptance of the SomnoDent® MAS therapy as an effective treatment solution, compared to surgery or CPAP. We believe this product will demonstrate to mild, moderate and non-compliant CPAP patients that there is a non-invasive, comfortable and effective alternative.”

SomnoMed has signed a term sheet with Zephyr Sleep Technologies Inc. for exclusive worldwide distribution of the RCMP demonstrating its continued dominance of the Dental Sleep Medicine market. Subject to FDA approval, SomnoMed expects to begin selling the RCMP in North America and other international markets in the first half of 2011.

For more information contact:

Mr. Ralf Barschow, CEO, SomnoMed Limited +61 2 9467 0420

Mr. Peter Santosham, Director, Zephyr Sleep Technologies Inc. +1 403 270 2440



About Zephyr Sleep Technologies Inc. ("Zephyr")

Zephyr researches and develops products designed to monitor and analyze sleep performance and treat certain sleep disorders using patented and proprietary technology. Working with a diverse world-wide community of sleep technicians, medical professionals, distributors and manufacturers, Zephyr's products provide solutions to sleep-related problems. Zephyr is a private Calgary, Alberta, Canada-based company.

For more information, please visit www.zephyrsleep.com.